Venetoclax
- BNF:
- Not listed
- Status:
- Red
- Decision Date:
- February 2017
Comments
RED:
- NICE TA487 - for treating chronic lymphocytic leukaemia. (Decision date - December 2017)
- NICE TA561 - with rituximab for previously treated chronic lymphocyctic leukaemia. (Decision date - March 2019)
- NICE TA663 - Venetoclax with obinutuzumab
for untreated chronic lymphocytic leukaemia. (Decision date - January 2021)
- Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Decision date - February 2021)
- NICE TA765 - Venetoclax with azacitidine for untreated acute myeloid
leukaemia when intensive chemotherapy is unsuitable. (Decision date - March 2022)
- NICE TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (Decision date - May 2022)
- NICE TA796 - Venetoclax for treating chronic lymphocytic leukaemia. NHSE
commissioned. (Decision date - July 2022)
NHSE commissioned drug.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again